U-Medico Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
U-Medico Inc. - overview
Established
2006
Location
Osaka-shi, -, Japan
Primary Industry
Biotechnology
About
Based in Osaka, Japan, and founded in 2006, U-Medico Inc. operates as a provider of analytical and formulation development services to biopharmaceutical and gene therapy companies, supporting drug development from research to manufacturing and approval. In October 2024, AS ONE CORPORATION acquired an undisclosed stake in U-Medico Inc. As of 2024, the company is led by its CEO, Ayano Fukuhara.
The company provides a wide range of biopharmaceutical and gene therapy services, such as biophysical characterization and ultracentrifugation (AUC). Moreover, the firm offers hydrogen deuterium exchange mass spectrometry (HDX-MS), particle and aggregate analysis, formulation development, and stability studies. Additionally, the firm also provides services such as gene therapy analysis and quality testing for the stable production of gene and cell therapies.
Current Investors
AS ONE, Shimadzu Corporation
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.u-medico.co.jp/
Total Amount Raised
Subscriber access only
U-Medico Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| LP Direct | Completed | U-Medico Inc. | - | ||||||||
| LP Direct | Completed | U-Medico Inc. | - |
Displaying 1 - 2 of 2
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.